New semantics in GoPubMed and European biotech start-ups

Transinsight has announced the launch of GoPubMed.com version 4.0, the semantic search engine for the life sciences with significantly improved features.
  • Increased Speed: GoPubMed 4.0 is ten times faster than its predecessor, now handling millions of documents in seconds.
  • Intelligent search: Never miss a document. The new interactive filtering process reduces millions of documents to a handful of key papers in just a few clicks. The Web 2.0 query processing helps by suggesting search ideas as you type.
  • More document sources: The GoPubMed.com website offers searches on PubMed and the Web at no cost. The professional version of GoPubMed PRO is designed to include intranet searches and patents.
  • Improve GoPubMed: The public website GoPubMed.com allows users to manually annotate and verify papers including their background information. The platform has already about 60.000 enthusiastic helping hands. GoPubMed shows the semantic path to the future: community generated ontologies and so improves the quality of search results.

"GoPubMed PRO for corporate semantic searches can handle multiple ontologies represented in many languages. The integrated semi-automated ontology generation tool helps to create ontologies of unknown domains much faster than doing them by hand. Local intranet and desktop searches will help our customers extend the power of the semantic search technology to their local information pools which helps reduce the time needed for manual information retrieval significantly. Cutting down the average hours spent weekly (12.4) on information searches to a little more than 1 hour can be directly expressed in terms money spent." explains Dr. Liliana Barrio-Alvers, CTO at Transinsight. "This is what our customers appreciate: greater efficiency that translates into faster and higher returns on their investments."

The judges of the European Venture Summit, which took place 1 & 2 December 2008 in Düsseldorf, Germany, ranked Transinsight and GoPubMed PRO as one of the Top 5 presenters in Biotech.

GoPubMed builds on cutting edge research developed in cooperation with TU Dresden in the EU project Sealife and is supported by INNO-WATT. For more information go to: www.GoPubMed.com.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honored with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...